• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[淋巴肉芽肿病的新诊断与治疗方面]

[New diagnostic and therapeutic aspects of lymphogranulomatosis].

作者信息

Helbig W

出版信息

Z Gesamte Inn Med. 1976 Apr 15;31(8):232-9.

PMID:960900
Abstract

The prognosis of lymphogranulomatosis has improved by the considerably improved diagnostics as well as the modern radiological and polychemo-therapeutical methods. Today the average survival time is between 4 and 5 years. But survival times up to 15 years and more are described. Apart from the early diagnosis, into which according to the opinion of many internal specialists the otorhinolaryngologists must be included more than it was hitherto the case, nowadays the modern radiotherapy with explorative laparotomy and splenectomy and the perhaps following combination chemotherapy might bring a further improvement. Growing age, histological types with a small number of lymphocytes, too late diagnosis and deficient control decrease, however, signigicantly the chances of surviving. Certainly, in future more modern methods of chemotherapy must be used. The same applies to the treatment of the developing immunoinsufficiency and the eventual further performance of the cytostatic treatment in the sense of a maintenance therapy. From the modern point of view the way taken might lead to still higher survival times. In as far immunotherapy will be of greater importance already in the next years is not yet to be decided at present.

摘要

随着诊断技术的显著改进以及现代放射学和多化疗方法的应用,淋巴肉芽肿的预后已有所改善。如今,平均生存时间在4至5年之间。但也有生存时间长达15年及以上的报道。除了早期诊断(许多内科专家认为耳鼻喉科医生在其中的参与度应比以往更高)之外,如今采用探索性剖腹术和脾切除术的现代放疗以及随后可能进行的联合化疗或许会带来进一步的改善。然而,年龄增长、淋巴细胞数量少的组织学类型、诊断过晚以及控制不足都会显著降低生存几率。当然,未来必须采用更现代的化疗方法。这同样适用于对免疫功能不全发展的治疗以及从维持治疗角度最终进一步进行的细胞抑制治疗。从现代观点来看,所采取的方法可能会带来更高的生存时间。至于免疫疗法在未来几年是否会变得更加重要,目前尚未确定。

相似文献

1
[New diagnostic and therapeutic aspects of lymphogranulomatosis].[淋巴肉芽肿病的新诊断与治疗方面]
Z Gesamte Inn Med. 1976 Apr 15;31(8):232-9.
2
The effect of chemotherapy (MOPP) following radiotherapy in stage I to III Hodgkin's disease: analysis of 110 cases.
Haematologica. 1979 Feb;64(1):50-60.
3
[Lymphogranulomatosis. Basic characteristics of diagnosis, therapy and prognosis (author's transl)].[淋巴肉芽肿病。诊断、治疗及预后的基本特征(作者译)]
Rontgenblatter. 1974 Sep;27(9):429-39.
4
[Radiotherapy of lymphogranulomatosis].[淋巴肉芽肿病的放射治疗]
Internist (Berl). 1974 Feb;15(2):85-92.
5
[A multivariate prognosis model for Hodgkin disease].
Strahlentherapie. 1984 Sep;160(9):535-42.
6
[Effect of an energy-rich radiotherapy (60Co) or chemotherapy on the PHA stimulation of lymphocytes in patients with Hodgkin's disease or bronchial carcinoma].
Verh Dtsch Ges Inn Med. 1974;80:1683-5.
7
[Radiotherapy of Hodgkin's disease. Results of radical megavolt therapy with large fields in comparison with conventional orthovolt therapy. 1. Results of Freiburg patients from 1948 to 1964 and from 1964 to 1969].
Strahlentherapie. 1971 Apr;141(4):381-9.
8
[Statistical results of cobalt therapy in Hodgkin's disease].
J Radiol Electrol Med Nucl. 1974 Jun-Jul;55(6-7):533.
9
[Prognostic factors during control of the course of lymphogranulomatosis: comparison of 2 therapy technics and analysis of serologic parameters].
Strahlentherapie. 1985 Apr;161(4):221-4.
10
[Survival rates in lymphogranulomatosis related to different methods of primary treatment (author's transl)].
Arch Geschwulstforsch. 1981;51(5):411-7.